<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780323</url>
  </required_header>
  <id_info>
    <org_study_id>CELB_RA_IV</org_study_id>
    <nct_id>NCT02780323</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IV clinical study is to Compare the Efficacy and Safety of CELBESTA® and CELEBREX®
      in Rheumatoid Arthritis Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thisi is a multi-center, double-blind, active-controlled, randomized, parallel-group clinical
      trial to compare the efficacy and safety of CELBESTA® and CELEBREX® in patients with
      rheumatoid arthritis. The subject will receive two tablets twice daily for 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of 100mm VAS about pain in study at week 6</measure>
    <time_frame>week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of DAS28-ESR(Disease Activity Score in 28 joints) at week 6</measure>
    <time_frame>week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CELBESTA® and CELEBREX® placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CELEBREX®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CELBESTA®</intervention_name>
    <description>1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks</description>
    <arm_group_label>CELBESTA® and CELEBREX® placebo</arm_group_label>
    <other_name>celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CELEBREX®</intervention_name>
    <description>1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks</description>
    <arm_group_label>CELEBREX®</arm_group_label>
    <other_name>celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CELEBREX® placebo</intervention_name>
    <description>1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks</description>
    <arm_group_label>CELBESTA® and CELEBREX® placebo</arm_group_label>
    <other_name>celecoxib placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CELBESTA® placebo</intervention_name>
    <description>1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks</description>
    <arm_group_label>CELEBREX®</arm_group_label>
    <other_name>celecoxib placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anyone over the age of 19

          -  Subjects who are diagnosed as established rheumatoid arthritis at screening visit and
             before

          -  Pain greater than 40/100mm-VAS(Visual Analgue Scale) after wash-out period

          -  Patients who are taking oral corticosteroids without dosage change (within a range of
             prednisolone 10mg a day) at least 4weeks and more than 1 DMARDs at least 3 months from
             screening test

          -  Patients willing and able to provide signed informed consent after the nature of the
             study has been explained

        Exclusion Criteria:

          -  History of angina pectoris or congestive heart failure at rest or minimum activity

          -  History of myocardial infarction or artherosclerosis

          -  Patients who had a coronary angioplaty or coronary artery bypass graft within 1 year

          -  History of stroke, transient ischemic attack or hepatitis within 2 years

          -  Patients who have uncontrolled hypertension at screening

          -  Patients who take the medicines that might effect the test results by study
             investigators or might cause a excessive risk to the patients

               -  Intra-articular corticosteroid injection within 4 weeks from screening

               -  biological DMARDs such as infliximab, adlimumab, entanercept, anakinara or
                  abatacept wihin 6 months from randomization

               -  biological DMARDs such as rituximab within 1 year from randomization

          -  History of a malignant tumor (except for the patients whose tumor was removed and
             there's no recurrence within 5 years)

          -  Patients who have gastrointestinal bleeding or peptic ulcer (except scar) within 30
             days

          -  History of a gastroesophageal surgery such as antigastric-secretion surgery or
             esophagogastrectomy (except a simple perforator surgery)

          -  Patients who have severe disability in GI, Kidney, Liver and Blood

          -  Pregnant women, Lactating women and Women of child-bering potential who are not using
             adequate means of contraception

          -  History of allergy to COX-2 inhibitors or sulphonamides or other NSAIDs

          -  Any condition that, in the view of the investigator, would interfere with study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-jae Hong, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sungsoo Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangneung Asan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sangil Lee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Changnam Son, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeong Ho Seo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geun-Tae Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kosin University Gospel Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin-Wuk Hur, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Eulji Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyun-Sook Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myeong Soo Lee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yun Sung Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chosun University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-jae Hong, MD,PhD</last_name>
    <phone>+82-2-958-8200</phone>
    <email>hsj718@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mihwa Han, Bachelor</last_name>
    <phone>+82-2-958-8087</phone>
    <email>bfhan68@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohyun Park, Bachelor</last_name>
      <phone>+82-2-958-8087</phone>
      <email>pppp14v@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Celecoxib</keyword>
  <keyword>CELBESTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

